Inclusion of Brazil’s healthcare sector into WTO’s GPA uncertain



According to the Brazilian Association of Industrial Fine Chemicals and Biotechnology (ABIFINA), Brazil has not explicitly excluded the healthcare sector tenders, such as those launched by the Unified Health System (SUS), from its market access offer to the World Trade Organization (WTO) regarding the latter’s Agreement on Government Procurement (GPA). The possibility remains that government procurement processes for health products could enter the mechanism’s guidelines, since the text of the offer is currently only available to GPA members.

GPA is an international instrument regulating the conduct of international trade in government procurement markets, aiming to ensure fair, transparent, and non-discriminatory conditions of competition for purchases, according to WTO. GPA members include Armenia, Aruba (Netherlands), Australia, Canada, Hong Kong (China), Iceland, Israel, Japan, Korea, Liechtenstein, Moldova, Montenegro, New Zealand, Norway, Singapore, Switzerland, Taiwan (China), Ukraine, United Kingdom, US, as well as the European Union and its members Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxemburg, Malta, Netherlands, Poland, Portugal, Romania, Slovak Republic, Slovenia, Spain, Sweden.

Reference:

Related news
Brazil’s Ministry of Health (MoH) last week signed a contract with local pharmaceutical company Precisa Medicamentos for the purchase of 20 million doses of Indian partner Bharat Biotech’s SARS-CoV-2 vaccine Covaxin, totalling BRL 1.6 billion (USD 288 million).
Argentina’s Ministry of Health (MoH) last week launched two direct drug purchases aimed at procuring contraceptives from Bayer.
Panama’s Inversiones y Servicios Nacionales, a supplier of medicines and pharmaceutical products, last week filed a claim of unconstitutionality with the Supreme Court against the Social Security Fund (CSS), the health plan that covers 80% of the population, over new requirements to participate in a drug tender to supply the CSS for 1 year.
The Russian Direct Investment Fund (RDIF) this week announced receipt of emergency use authorizations (EUAs) from Guatemala’s Ministry of Health (MSPAS), Guyana’s Ministry of Health (MoH), and Honduras’s Sanitary Regulation Agency (ARSA) for its SARS-CoV-2 vaccine Sputnik V.
The Jiangxi provincial pharmaceutical procurement services platform released draft plans for "Drugs and Medical Consumables Sunshine Online Procurement Implementation Reform and Improvement Plan".
Recent news
Brazil’s Ministry of Health (MoH) last week signed a contract with local pharmaceutical company Precisa Medicamentos for the purchase of 20 million doses of Indian partner Bharat Biotech’s SARS-CoV-2 vaccine Covaxin, totalling BRL 1.6 billion (USD 288 million).
Argentina’s Ministry of Health (MoH) last week launched two direct drug purchases aimed at procuring contraceptives from Bayer.
Mexico-based pharmaceutical firm Genomma Lab last week released 2020 financials, reporting MXN 13.9 billion (USD 670 million) turnover after 9.1% year-on-year (YOY) growth, and flaunting minor negative impact of the COVID-19 pandemic.
  • 1614588392046
  • Argentina,Brazil,Colombia,Chile,Puerto Rico ,Costa Rica,Panama,Peru,Paraguay,Uruguay,Ecuador ,Bolivia ,Mexico,Guatemala,Honduras,El Salvador,Belize,Nicaragua
  • Company
Argentine pharmaceutical company Richmond last week signed a memorandum of understanding (MoU) with the Russian Direct Investment Fund (RDIF) for the local manufacturing of the latter’s SARS-CoV-2 vaccine Sputnik V, which was rolled out in the country in December last year.
China's Center for Drug Evaluation (CDE) website indicates that FutureGen Biopharma’s M108, a claudin 18.2 (CLDN18.2) targeted monoclonal antibody (mAb), has passed the clinical trial approval process and will be assessed in general advanced solid tumors.
German giant Bayer HealthCare entered into a memorandum of understanding with the China Alliance of Rare Diseases (CARD).
Beijing-based DaWei Biotechnology, a microfluidic technology driven molecular diagnostics specialist, struck a partnership with leading domestic in vitro diagnostics company Maccura Biotechnology Co., Ltd (300463.SZ) on next-generation molecular diagnostics technologies.
Analytics Snapshot


Analytics Snapshot